Circadian rhythms in major depressive disorder: mechanistic insights and therapeutic frontiers

Major Depressive Disorder (MDD) has emerged as a leading cause of disability worldwide, affecting over 264 million people. Recent evidence reveals that disruption of circadian rhythms may be fundamental to MDD pathophysiology, opening new avenues for therapeutic intervention.

This review synthesizes current understanding of the intricate relationship between circadian system disruption and MDD, highlighting molecular mechanisms and clinical implications. We examine evidence from genetic studies, clinical observations, and therapeutic trials.

Patients with MDD exhibit profound alterations in circadian-regulated processes, including sleep-wake cycles, diurnal mood patterns, and metabolic functions. Genetic studies have identified variants in core clock genes, particularly CLOCK, TIMELESS, and CRY1, that correlate with both circadian disruption and MDD susceptibility. These genetic insights, combined with evidence of dysregulated hypothalamus-pituitary-adrenal axis function and abnormal melatonin signaling, suggest that circadian dysfunction may be causal in MDD pathogenesis rather than merely symptomatic.

Emerging chronotherapeutic approaches, such as light therapy, sleep interventions, and targeted pharmacology, show significant potential for improving depressive symptoms. Personalized circadian-based treatments, guided by genetic and molecular markers, could transform MDD care. Advancing our understanding of the circadian-depression connection offers a promising path to revolutionizing treatment strategies.